Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Takeda
Baylor College of Medicine
HistoSonics, Inc.
Stanford University
University of Southern California
University of Washington
Massachusetts General Hospital
National Institutes of Health Clinical Center (CC)
Thomas Jefferson University
Federation Francophone de Cancerologie Digestive
Bayer
Thomas Jefferson University
Intensity Therapeutics, Inc.
Georgetown University
Alliance for Clinical Trials in Oncology
Sirtex Medical
Fox Chase Cancer Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Imunon
VA Office of Research and Development
Ethicon, Inc.
National Institutes of Health Clinical Center (CC)
Pfizer
Imunon
Pfizer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ethicon, Inc.
Basilea Pharmaceutica
Eisai Inc.
Massachusetts General Hospital
Memorial Sloan Kettering Cancer Center
Stanford University
Eastern Cooperative Oncology Group
Novartis
Basilea Pharmaceutica
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company
Emory University
Northwestern University
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
Imunon
Big Ten Cancer Research Consortium
BTG International Inc.
Cellxpert Biotechnology Corp.
Wake Forest University Health Sciences